Options Trading News

October 12, 2012  Fri 7:31 AM CT


Drug Progresses to Final Stage of Testing

Lexicon Pharmaceuticals reported positive data for its drug that treats carcinoid tumors. It's now moving from Phase 2 trials to Phase 3 trials, sending LXRX higher by 13 percent in the premarket.

Infosys Sees Weaker Profit

Infosys now expect full-year earnings of $2.97 a share, versus its previous forecast of $3.03.The outsourcing company also failed to raise it revenue guidance as analysts had hoped. INFY drops 5 percent in early trading.

J.B. Hunt Revenue Beats Expectations

J.B. Hunt Transport Services had third-quarter revenue of $1.30 billion, beating the $1.28 billion estimate. Profit missed expectations, but investors are focusing on that strong top-line number and sending JBHT higher by about 5 percent in the premarket.

Weak PC Market Drags on AMD

Advanced Micro Devices preannounced that third-quarter revenue fell by about 10 percent. It had previously forecast a decline of no more than 4 percent. Management cited a weakening PC market, and AMD is lower by 9 percent in the pre.

Share this article with your friends


Premium Services

Education & Strategy

The art of trading

As I stated in last week's article, a break out or a break down needs to have a couple things happen before it is considered a confirmed break out or break down. The only problem is that in today's market where things move much more quicker than they did just a few years ago, two days could wind up being the majority of the expected movement, if not the whole movement.

View more education articles »